# Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

> **NCT06079164** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 39 (estimated)

## Conditions studied

- Relapsed/Refractory Large B-cell Lymphoma

## Interventions

- **DRUG:** KITE-197
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06079164
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079164, "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT06079164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*